Mesa Laboratories Projects $250 Million to $255 Million in Fiscal 2027 Revenue

Mesa Laboratories, Inc. projected fiscal 2027 revenue of $250 million to $255 million on Nov. 9, signaling little sales growth even as it expects adjusted EBITDA to rise faster than revenue.

For the year ending March 31, Mesa expects revenue growth of 0% to 2% and adjusted EBITDA of $66 million to $68 million, an increase of 5% to 8%. The outlook anticipates lower Clinical Genomics revenue and excludes restructuring charges.

The adjusted EBITDA forecast reflects Mesa’s October cost reduction plan. Under that plan, the quality control and life sciences tools company aims to cut annual operating costs by about $9.3 million and reinvest approximately $4.3 million in growth initiatives. Mesa expects about $5 million in net annual savings after the reinvestment.

For its fiscal second quarter, which ended Sept. 30, revenue rose 2.6% from a year earlier to $62.3 million. Net income increased 75.3% to $4.3 million, and adjusted EBITDA grew 21.1% to $17.3 million.

Mesa expects third-quarter revenue to be roughly unchanged from a year earlier as Clinical Genomics sales decline.

The company also announced a board authorization, approved Nov. 4, to repurchase up to $40 million of its shares. Mesa expects to fund any purchases with cash on hand and cash from operations. The authorization does not require the company to buy shares and expires Dec. 31, 2028.